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We have developed a transcriptome-wide approach to identify genes affected by promoter CpG island DNA
hypermethylation and transcriptional silencing in colorectal cancer. By screening cell lines and validating tumor-
specific hypermethylation in a panel of primary human colorectal cancer samples, we estimate that nearly 5% or more
of all known genes may be promoter methylated in an individual tumor. When directly compared to gene mutations,
we find larger numbers of genes hypermethylated in individual tumors, and a higher frequency of hypermethylation
within individual genes harboring either genetic or epigenetic changes. Thus, to enumerate the full spectrum of
alterations in the human cancer genome, and to facilitate the most efficacious grouping of tumors to identify cancer
biomarkers and tailor therapeutic approaches, both genetic and epigenetic screens should be undertaken.
Citation: Schuebel KE, Chen W, Cope L, Glo ¨ckner SC, Suzuki H, et al. (2007) Comparing the DNA hypermethylome with gene mutations in human colorectal cancer.
PLoS Genet 3(9): e157. doi:10.1371/journal.pgen.0030157
Introduction
It is now well established that loss of proper gene function
in human cancer can occur through both genetic and
epigenetic mechanisms [1,2]. The number of genes mutated
in human tumor samples is being clariﬁed. Recently, Sjo ¨blom
et al. [3] sequenced 13,023 genes in colorectal cancer (CRC)
and breast cancer, and estimated an average of 14 signiﬁcant
mutations per tumor, suggesting that a relatively small
number of genetic events may be sufﬁcient to drive tumori-
genesis. In contrast, the full spectrum of epigenetic alter-
ations is not well delineated. The best-deﬁned epigenetic
alteration of cancer genes involves DNA hypermethylation of
clustered CpG dinucleotides, or CpG islands, in promoter
regions associated with the transcriptional inactivation of the
affected genes [2]. These promoters are located proximal to
nearly half of all genes [4] and are thought to remain
primarily methylation free in normal somatic tissues. The
exact number of such epigenetic lesions in any given tumor is
not precisely known, although a growing number of screening
approaches, none covering the whole genome efﬁciently, are
identifying an increasing number of candidate genes [5–13].
Given the large number of potential target promoters present
in the genome, we hypothesized that many more hyper-
methylated genes await discovery.
Herein, we describe a whole human transcriptome micro-
array screen to identify genes silenced by promoter hyper-
methylation in human CRC. The approach readily identiﬁes
candidate cancer genes in single tumors with a high efﬁciency
of validation. By comparing the list of candidate hyper-
methylated genes with mutated genes recently identiﬁed in
CRC [3], we establish key relationships between the altered
tumor genome and the gene hypermethylome. Our studies
provide a platform to understand how epigenetic and genetic
alterations drive human tumorigenesis.
Results
Developing the Whole Transcriptome Approach
Our ﬁrst step towards a global identiﬁcation of hyper-
methylation-dependent gene expression changes was made by
comparing, in a genome-wide expression array-based ap-
proach, wild-type HCT116 CRC cells with isogenic partner
cells carrying individual and combinatorial genetic deletions
of two major human DNA methyltransferases (Figure 1A) [14].
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( / )DNMT3B
( / ) double knockout
(DKO) HCT116 cells, which have virtually complete loss of
global 5-methylcytosine, all previously individually examined
hypermethylated genes lacking basal expression in wild-type
cells undergo promoter demethylation with concomitant
gene re-expression [10,14–16]. By stratifying genes according
to altered signal intensity on a 44K Agilent Technologies
array platform, we observe a unique spike of gene expression
increases in the DKO cells when compared to the isogenic
wildtype parental cells, or isogenic cell lines in which DNMT1
or DNMT3B have been individually deleted and which harbor
minimal changes in DNA methylation (Figure 1B). This
minimal change in the DNMT1
( / )cells may, in part, be due
to recently identiﬁed alternative transcripts arising from the
DNMT1 locus [17,18].
We tested our approach using a pharmacologic strategy
based on our previous approach [10], but now markedly
modiﬁedtoprovidewhole-transcriptomecoverage,toidentify
silenced hypermethylated genes in any cancer cell line. For
densely hypermethylated and transcriptionally inactive genes,
the DNA demethylating agent 5-aza-29-deoxycytidine (DAC)
has a well established capacity to induce gene re-expression
[19,20].On theotherhand, forthesesamegenes,theclassIand
II histone deacetylase inhibitor, trichostatin A (TSA) will not
alone induce reexpression [10,21]. Wenow use thislack of TSA
response for such genes to provide a new informatics ﬁlter to
identifythemajorityofDNAhypermethylatedgenesincancer.
After treatment of HCT116 cells with either DAC or TSA
(Figure 1C), we identiﬁed a zone in which gene expression did
not increase with TSA (,1.4-fold) and displayed no detectable
expressioninmock-treatedcells.Withinthiszone,weobserved
a characteristic spike of DAC-induced gene expression that
virtually completely encompasses the genes with increased
expression in DKO cells (compare yellow spots in Figure 1D
with blue spots in Figure 1B). This gene spike is absolutely
dependent upon analysis of only genes that fail to respond to
histone deacetylase inhibition, underscored by a cluster
analysis that shows the close relationship between genes in
DKO-and DAC-treated cellswith a separate grouping of gene-
expression changes after TSA treatment alone or in single
knockouts (Figure 1E). These data conﬁrm previous studies
covering much less of the genome, and using only treatment of
cells with DAC and TSA together, in which genes with dense
CpG islands that were reexpressed by TSA harbored only
partial or no detectable hypermethylation [10,21].
Importantly, a similar spike of gene expression increases
could be seen in ﬁve additional human CRC cell lines, SW480,
CaCO2, RKO, HT29, and COLO320 (Figure 2A), as well as cell
lines derived from lung, breast, ovary, kidney, and brain
(unpublished data), conﬁrming that this approach works
universally in cancer cell lines and identiﬁes overlapping
gene sets (Figure 2C). However, it is important to note that—
possibly because DAC incorporates into the DNA of dividing
cells, and our treatments were performed for only 96 h—
sensitivity for detecting the gene increases in the pharmaco-
logical approach is reduced in HCT116 cells compared to that
seen in DKO cells (Figure 1D). To address the sensitivity with
which our new array approach identiﬁes CpG island hyper-
methylated genes, we ﬁrst examined 11 genes known to be
hypermethylated, completely silenced and reexpressed after
DAC treatment in HCT116 cells (Figure 3A). All tested genes
remained within the TSA nonresponsive zone (Figure 3B), and
the direction of expression changes correlated well in DAC
treated and DKO cells (Figure 3C). Importantly, for the DAC
increase, ﬁve of the guide genes (45%) increased 2-fold or
more and three more genes, or a total of 73%, increased 1.3-
fold or more (Figure 3D). We estimate, then, that we can detect
over 70% of DNA hypermethylated genes in a given cancer
cell line and we test this hypothesis in studies directly below.
Figure 1. Approach for Identification of the Human Cancer Cell Hypermethylome in HCT116 CRC Cells
(A) RNA from the indicated cell lines was isolated, labeled, hybridized, scanned, and fluorescent spot intensities normalized by background subtraction
and Loess transformation using Agilent Technologies 44K human microarrays. Parental wild-type HCT116 cells (WT) and isogenic knockout counterparts
for DNA methyltransferase 1 (DNMT1
 / )o r3 b( DNMT3B
 / ) are compared in our study. DKO cells are doubly deficient for both DNMT1 and DNMT3B.
(B) Gene-expression changes in HCT116 cells with genetic disruption of various DNA methyltransferases. A 3-D scatter plot indicating the gene-
expression levels in HCT 116 cells with genetic disruption of DNMT1 (x-axis), DNMT3B (z-axis), and both DNMT1 and DNMT3B (DKO; y-axis) in fold scale.
Individual gene-expression changes are in black with the average for three experiments (red spots) or from an individual experiment (blue spots) for
those genes in DKO cells with greater than 4-fold expression change.
(C) HCT116 cells were treated with 300 nM TSA for 18 h or 5 lM DAC for 96 h and processed as described above.
(D) Gene-expression changes for HCT116 cells treated with TSA (x-axis) or DAC (y-axis) are plotted by fold change. Yellow spots indicate genes from
DKO cells with 2-fold changes and above. Notice the loss of sensitivity when compared to gene-expression increases seen in DKO cells (80% of genes
greater than 4-fold in the DKO cells now becomes greater than 1.3-fold in DAC-treated cells). Green spots indicate randomly selected genes verified to
have complete promoter methylation in wild-type cells, reexpression in DKO cells and after DAC treatment, while red spots indicate selected genes that
were identified as false positives (See Figures 4, 6, and 7 for validation results). Blue spots indicate the location of the 11 guide genes—previously
shown to be hypermethylated and completely silenced in HCT 116 cells—used in this study (see Figure 3 for description). A distinct group of genes,
including five of 11 guide genes, displays increases of greater than 2-fold after DAC treatment but no increase after TSA treatment. These genes form
the top tier of candidate hypermethylated genes as discussed in the text.
(E) Relatedness of whole-transcriptome expression patterns identified by dendrogram analysis. Individual single genetic disruption of DNMT1 and
DNMT3B, DKO and DAC treatment, and TSA treatment each form three distinct categories of gene expression changes.
doi:10.1371/journal.pgen.0030157.g001
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Author Summary
Loss of gene expression in association with aberrant accumulation of
5-methylcytosine in gene promoter CpG islands is a common feature
ofhumancancer.Here,wedescribeamethodtodiscoverthesegenes
that permits identification of hundreds of novel candidate cancer
genes in any cancer cell line. We now estimate that as much as 5% of
colon cancer genes may harbor aberrant gene hypermethylation and
we term these the cancer ‘‘promoter CpG island DNA hyper-
methylome.’’ Multiple mutated genes recently identified via cancer
resequencing efforts are shown to be within this hypermethylome
andtobemorelikely toundergoepigeneticinactivationthangenetic
alteration. Our approach allows derivation of new potential tumor
biomarkers and potential pathways for therapeutic intervention.
Importantly, our findings illustrate that efforts aimed at complete
identification of the human cancer genome should include analyses
of epigenetic, as well as genetic, changes.PLoS Genetics | www.plosgenetics.org September 2007 | Volume 3 | Issue 9 | e157 1711
Gene Hypermethylation and MutationsValidating the Methylation Status of Candidate Genes
Derived from the Screening Approach
Based on the sensitivity differences observed between
DKO- and DAC -induced gene increases (compare Figure
1B and D; also Figure 3B and 3C) and behavior of the guide
genes in the array platform, we designated, within the TSA-
negative zone, a top tier (2-fold increase or above) and a next
tier of genes (increasing between 1.4- and 2-fold) to identify
hypermethylated cancer genes (Figure 2B). Importantly, we
introduced an additional ﬁlter for selecting genes from these
zones based on their having no basal expression in untreated
cells, since this full lack of transcription is characteristic of
promoter CpG island methylated genes in cell culture.
Indeed, based on these selection criteria, in HCT116 cells,
32 of 35 (91%, Figure 4) of randomly chosen CpG island–
containing genes spanning the top-tier response zone of 532
genes (Figure 5), and 31 of 48 such SW480 cell genes (65%,
Figure 6) from among 318 top tier genes proved to be CpG
hypermethylated as measured by methylation-speciﬁc PCR
(MSP) [22], and silenced in the cell line of origin as measured
by reverse transcriptase PCR (RT-PCR). We also examined the
efﬁciency of discovery for hypermethylated genes in the next
Figure 2. Characterization of the Human Cancer Cell Hypermethylome in Different Human CRC Cell Lines
(A) Gene-expression changes for the indicated cells treated with TSA (x-axis) or DAC (y-axis) are plotted by log-fold change, and individual genes are
shown in black.
(B) Validation of the DNA hypermethylome. The characteristic spike of hypermethylated genes defined by treatment of cells with DAC or TSA consists of
two tiers, with distinct features. The top tier of genes was identified as a zone in which gene expression did not increase with TSA (,1.4 fold) and
displayed no detectable expression in wild-type cells, but increased greater than 2-fold with DAC treatment. The next tier of genes was identified as a
cluster of genes for which expression changes of TSA and wild type were identical to those in the top tier, but increased between 1.4-fold and 2-fold
with DAC treatment. Gene expression validation by RT-PCR and MSP indicated a validation frequency of 91% for top-tier genes in HCT116 cells,
including genes that increased in DKO cells by greater than 2-fold. Next-tier genes in HCT116 cells were confirmed at a frequency of 49%, and in the
SW480 top tier, with a frequency of 65%.
(C) Shared candidate hypermethylated genes in CRC cell lines. We identified a total of 5,906 unique genes in all six cell lines with expression changes
falling within the criteria of top- or next-tier categories. Overlaps in gene expression changes among two, three, four, five, or six cell lines are indicated;
these range from 1,414 genes shared among two cell lines to 78 genes that were shared among all six cell lines.
doi:10.1371/journal.pgen.0030157.g002
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Gene Hypermethylation and Mutationstier of DAC-treated HCT116 cells. Of the 1,190 genes
identiﬁed in this region, 17 of 35 (49%) randomly selected
genes containing a CpG island were hypermethylated with
concordant gene silencing (Figure 7). Our veriﬁcation rates
then demonstrate around 65% efﬁciency of our approach,
which is close to our original estimate and which is excellent
compared to previous screens for identifying new cancer
hypermethylated genes [6,23]. With this level of veriﬁed
hypermethylation, we calculate that the hypermethylome in
HCT116 cells consists of an estimated 1,067 genes and an
estimated 579 genes for the SW480 cells (See Table S1 for a
detailed description of calculations). The hypermethylome
would be estimated to range from 532 genes in CaCO2 to
1,389 genes in RKO cells (Table S1).
We next asked whether our top and next-tier regions truly
enriched for hypermethylated genes by examining a randomly
Figure 3. Guide Genes Used in This Study
(A) Gene names, Agilent Technologies probe name, Genbank accession number, and references for the 11 guide genes previously shown to be
hypermethylated and completely silenced in HCT116 cells.
(B, C) Blue spots and gene names indicate the location of the 11 guide genes in a plot of TSA (x-axis) versus DAC (y-axis) gene expression changes on a
log scale (B) or fold-change (C) scale. Five of 11 guide genes, circled in green, display increases of greater than 2-fold after DAC treatment but no increase
after TSA treatment and these same genes have greater than 3-fold increases in DKO cells (green circle)
(D) Direct comparison of guide genes in DKO and DAC plots. A distinct group of five guide genes, indicated by a green circle, showing greater than 3-
fold expression changes in DKO cells and greater than 2-fold in DAC-treated cells, define the upper tier of candidate hypermethylated genes as
discussed in the text. Another three genes increased 1.3-fold, and three failed to increase with DAC treatment, allowing criteria for the next tier of gene
expression to be established as described in the text.
doi:10.1371/journal.pgen.0030157.g003
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Gene Hypermethylation and Mutationsselected subset of 22 control genes located outside these
zones. These genes were located in the responsive TSA zones
(Zones 1 and 2, Figure S1A) or below the threshold of DAC
responsiveness in the TSA nonresponsive zone (Zone 3, Figure
S1A) in HCT116 cells. Of the tested genes, only 9% (2 of 22,
Figure S1B) showed detectable methylation with concomitant
gene silencing, conﬁrming the speciﬁcity of our approach and
validating the criteria we used to establish the top and next-
tier approach. We can then predict that for cancer cell lines,
with use of our ﬁlters, ;90% of promoter CpG island DNA
methylated genes lie in the negative TSA-responsive zone.
A fundamental question in cell culture–based approaches is
whether they identify genes that are targets for inactivation in
primary tumors. To address this, 20 CpG island containing
genes from the veriﬁed gene lists were randomly selected from
the HCT116 top tier (17 genes), HCT116 next tier (two genes),
or SW480 top tier (one gene) and analyzed for methylation in
a panel of CRC cell lines. All of the tested genes were
hypermethylated in two or more cell lines (Figure 8). We then
examined the status of these 20 genes in a panel of 20 to 61
primary colon cancers and 20 to 40 normal-appearing colon
tissue samples obtained from cancer-free individuals. Most of
the genes (65%) were completely unmethylated or rarely
methylated in the normal colonic tissue samples, but were
methylated in a vast majority (86%) of the primary tumors
(Figure 8). Of the 20 genes analyzed, 13 genes (65%) satisﬁed
Figure 4. Verification of the HCT116 Top Tier Hypermethylome
List of HCT116 candidate hypermethylated genes selected for verification of expression (by RT-PCR of HCT116 and DKO cells) and promoter methylation
(by MSP of HCT116 and DKO cells) status. Gene descriptions are indicated on the left side of the panel and gene names are shown next to the PCR
results. Water (RT-PCR and MSP), in vitro methylated DNA (for MSP), and actin beta (ACTB) were used as controls for each individual gene;
a representative sample is shown. Green arrows identify genes that verified the array results, red arrows those that did not.
doi:10.1371/journal.pgen.0030157.g004
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Gene Hypermethylation and Mutationscriteria for ‘‘tumor-speciﬁc methylation’’ with high-frequency
methylation in cell lines, low (,5%) or undetectable
methylation in normal colon, and frequent methylation in
primary tumor samples (Figure 8). The efﬁciency of our
strategy suggests a discovery rate of approximately one in two
for identiﬁcation of hypermethylated genes in cell lines and
approximately one in three for identiﬁcation of cancer-
speciﬁc hypermethylated genes. Our estimate of approxi-
mately 400 hypermethylated genes per primary tumor now
can be matched with predictions of Costello et al. [5] for
hypermethylation of CpG islands, based on screening with
Restriction Landmark Genomic Scanning approaches.
Validating Potential Biologic Relevance of Newly
Identified Genes
We next tested some parameters for biological signiﬁcance
of two of the genes harboring tumor-speciﬁc methylation for
their likely importance in primary colon cancers. One, the
neuralized homolog (Drosophila)( NEURL) gene, is located in a
chromosome region with high deletion frequency in brain
tumors [24], and its product has been identiﬁed as a ubiquitin
ligase required for Notch ligand turnover [25–27]. Activation
of this key developmental pathway inﬂuences cell-fate deter-
mination in ﬂies and vertebrates [28,29] and activation of
Notch, through unknown mechanisms, is thought to play an
inhibitory role in normal differentiation during colorectal
cancer [30]. The second gene, FOXL2, belongs to the forkhead
domain–containing family of transcription factors implicated
in diverse processes including establishing and maintaining
differentiation programs [31]. Intriguingly, this gene is
essential for proper ovarian development [32] and germline
mutations in humans lead to a plethora of craniofacial
anomalies and premature ovarian failure [33]. We ﬁnd both
of these genes to be frequently DNA hypermethylated in a
panel of colorectal cell lines (ﬁve of nine cell lines for NEURL
and seven of nine for FOXL2, Figure 9A and 9C), and bisulﬁte
sequencing revealed methylation of all CpG residues in the
central CpG island regions of both genes in HCT116 and RKO
celllines,withcompletedemethylationinDKOcells(Figure9B
and 9D). For both genes, this hypermethylation perfectly
correlatedwithlossofbasalexpressionandabilitytoreexpress
the genes with DAC treatment (Figure 9A and 9C). Impor-
tantly, promoter methylation of both genes, as assessed by
bisulﬁte sequencing (Figure 9B and 9D) is absent in normal
humancolonorrectum,butfrequentinprimarycoloncancers
(Figure9Eand9F),suggestingthathypermethylationaroseasa
cancer-speciﬁc phenomenon, although slight methylation was
observed at the FOXL2 locus in normal tissue from aged
patients (unpublished data). Finally, the pattern for hyper-
methylation of the FOXL2 and NEURL genes in cell culture ﬁt
with a biology important to a subset of colon cancers. As many
as one in eight colorectal cancers, predominantly those from
the right side of the colon, harbor a defect in mismatch-repair
capacity [34,35], primarily due, in nonfamilial cancers, to
inactivation of MLH1 by epigenetic mechanisms [36]. Such
tumors belong to a group with high frequency of hyper-
methylated gene promoters [37,38]. The hypermethylation of
FOXL2 and, especially, NEURL, aggregate with these tumor
types not only among the colon cancer cell lines (HCT116,
DLD1, LoVo, RKO, and SW48), but also when analyzed in a
series of primary human colon cancers (Fisher’s exact test
value of 0.024 for FOXL2 and 0.001 for NEURL, Figure 9G).
Initial in vitro studies suggest that both FOXL2 and NEURL
might possess tumor-suppressor activity. When overex-
pressed in colon cancer cell lines, full-length FOXL2 and
NEURL (Figure 10A and 10C), generate a 10-fold and 20-fold
reduction, respectively, in colony growth of HCT116 cells
(Figure 10C), with surviving clones having severely depleted
size (Figure 10B), comparable to results obtained with the
bona ﬁde tumor suppressor p53 (Figure 10F). Similar results
were seen in RKO and DLD1 cells (Figure 10D and 10E), both
of which have complete gene silencing at the FOXL2 and
NEURL loci. While the precise molecular mechanisms for the
growth suppression remains to be determined, Notch signal-
ing has recently been shown to play an important role in
differentiation of intestinal crypt cells where deletion of the
Notch effector molecule RBPJj or treatment with a highly
selective c-secretase inhibitor was found to be sufﬁcient for
conversion of crypt cells to goblet cells [28,29]. Similarly, the
closely related FOXL2 transcription factor family member
FOXL1 has recently been shown to play a role in epithelial–
mesenchymal transition of the intestinal epithelium [39].
Comparison of Newly Identified DNA Hypermethylated
Genes to Mutated Genes Identified from Sequencing of
Cancer Genomes
While it is clear that genetic and epigenetic mechanisms
are both important to initiation and progression of human
tumorigenesis, the relative contributions of each of these
alterations need to be clariﬁed on a global basis. Studies of
classic tumor suppressor genes such as VHL in renal cancer
and MLH1 in colon cancer indicate that important cancer
genes can have an incidence of inactivation by either genetic
Figure 5. Distribution of Verified HCT116 Top-Tier genes
Green spots show the location of individual genes with names indicated
in blue. The top tier of gene-expression changes within the spike shown
in Figure 1D has been magnified, and values for DAC and TSA expression
changes are shown in log scale.
doi:10.1371/journal.pgen.0030157.g005
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Gene Hypermethylation and Mutationsor epigenetic mechanisms [36,40]. However, a genome-wide
analysis to query such relationships has not been performed.
In a recent genome-wide sequencing of cancer genes,
Sjo ¨blom et al. [3] observed that newly discovered gene
mutations in colon and breast cancers generally had a low
incidence of occurrence, with 90% of the genes identiﬁed
harboring a mutation frequency of less than 10%. Further-
more, a typical patient’s colon or breast tumor was estimated
to have an average of only 14 mutations and there appeared
to be little overlap between individual tumors for the newly
discovered mutations [3]. These low frequencies raise the
question whether alternative mechanisms might account for
inactivation of these genes in additional tumors. Obviously,
the much higher number of candidate hypermethylated genes
we now identify in individual tumors suggests that this
epigenetic change might provide an alternative inactivating
route to mutations for many tumor suppressor genes. We
now show that screening tumors for both genetic and
epigenetic changes indicates that this is the case.
We ﬁrst located the 189 newly identiﬁed, mutated cancer
(CAN) genes, described by Sjo ¨blom et al. [3], within the top
and next tiers of our colorectal cancer cell line hyper-
Figure 6. Verification of the HCT116 Next Tier Hypermethylome
Genes were selected for verification of expression (by RT-PCR of HCT116 and DKO cells) and promoter methylation (by MSP of HCT116 and DKO cells)
status. Gene names are indicated on the left side of the panel and gene abbreviations are shown next to the PCR results. Water (RT-PCR and MSP),
in vitro methylated DNA (for MSP), and actin beta (ACTB) were used as controls for each individual gene; a representative sample is shown. Green arrows
identify genes that verified the array results, red arrows those that did not as discussed in the text.
doi:10.1371/journal.pgen.0030157.g006
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Gene Hypermethylation and Mutationsmethylome and found 56 genes present in these zones in one
or more of the cell lines. Of these, 45 contained CpG islands.
Twenty-six of these 45 genes (58%), similar to the veriﬁcation
rate for all candidate genes identiﬁed as discussed above,
proved to be hypermethylated in at least one of the six cell
lines, and were selected for further study. Importantly, exactly
half (13 of 26 genes) of these genes were expressed at high
levels (Figure 11A) and were not methylated in normal colon
(Figure 11B) but were methylated in primary CRC tumors
(Figure 11C), giving a frequency of 50% for identiﬁcation of
tumor-speciﬁc methylation when starting with genes harbor-
ing cell line methylation. We also randomly selected, for
Figure 7. Verification of the SW480 Top-Tier Hypermethylome
Genes were selected for verification of expression (by RT-PCR of SW480 and DAC-treated SW480 cells) and promoter methylation (by RT-PCR of SW480
and DAC-treated SW480 cells) status. Full gene names are indicated on the left side of the panel and abbreviated gene names are shown next to the
PCR results. Water (RT-PCR), in vitro methylated DNA (for MSP), and actin beta (ACTB) were used as controls for each individual gene; a representative
sample is shown. Green arrows identify genes that verified the array results, red arrows those that did not as discussed in the text.
doi:10.1371/journal.pgen.0030157.g007
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Gene Hypermethylation and Mutationsveriﬁcation of methylation and expression status in cell lines,
CAN genes that fell primarily in zone 3 of the microarray, that
is, within the TSA-negative zone but below the 1.4-fold cutoff
for stimulation by DAC. As seen earlier for other randomly
selected genes in this region, these randomly selected CAN
genes had a signiﬁcantly reduced (four of 15, or 27%)
frequency of methylation as compared to the 56 top and
next-tier CAN genes discussed above (Figure S1C). Interest-
ingly, however, this rate is much more similar to that for the
well-characterized hypermethylated guide genes (;30% as
shown in Figure 3A–3C) than for the other randomly selected
zone 3 genes (9%, compare Figure S1B and S1C), perhaps
indicating the importance of epigenetic inactivation of these
mutated genes. Indeed, relevant to this point, for the majority
of the examined CAN genes within the hypermethylome
region, the incidence of hypermethylation is strikingly higher
than that for mutations (Figure 11D). Thus, unlike for the
mutations in the individual genes, which are restricted to only
tumors from a few patients, hypermethylation for the majority
of the genes is a shared property between many tumors. These
ﬁndings of both mutations, and alternatively epigenetic
silencing, in these previously uncharacterized genes solidiﬁes
their probable roles as tumor suppressor genes.
Discussion
We describe a gene-expression approach with the capacity
to deﬁne, for any human cancer type for which representative
cell-culture lines are available, a substantial fraction of the
cancer gene promoter CpG island DNA hypermethylome.
Studies of these genes will contribute to understanding the
molecular pathways driving tumorigenesis; provide useful
new DNA hypermethylation biomarkers to monitor cancer
risk assessment, early diagnosis, and prognosis; and permit
better monitoring of gene reexpression during cancer
prevention and/or therapeutic strategies [41].
Through use of our approach to analyze mutated genes
identiﬁed by a genome-wide sequencing strategy, we docu-
ment that many more epigenetically altered genes than
genetically altered genes exist in any given tumor. The
importance of this fact emerges in our ﬁnding that for newly
discovered genes that are affected by both mechanisms, the
incidence for hypermethylation of any given gene among
colon cancers appears to be generally much higher than for
mutations. Interestingly, many of the new genes found by
Sjo ¨blom et al. [3] harbored heterozygous mutations and it
would be, thus, difﬁcult to predict whether the genes were
affected by activating or inactivating events from such data
alone. As ﬁrst suggested by Zardo et al. [42], our data may
clarify, in initial screening studies, the latter category, as
promoter DNA hypermethylation and gene silencing often
affect genes independent of loss of heterozygosity frequency.
Thus, discovery of genes targeted by hypermethylation as an
inactivating event should help guide prioritization of genes to
study in cancer gene resequencing efforts.
Finally, our data indicate that, in any given cancer type,
one may markedly underestimate both the full range of gene
alterations and associated abnormalities of cellular pathways
by failing to screen for both genetic and epigenetic
abnormalities. Our ﬁndings indicate that assessing both
mechanisms for loss of gene function indicates far more
sharing among individual colon tumors for pathway dis-
ruption than genetic analyses alone would predict. Optimal
approaches to grouping of tumors according to molecular
alterations in key pathways should, then, depend on deﬁning
both genetic and epigenetic gene changes. Thus, our ﬁndings
should encourage any genome-wide cancer gene screening
strategies to include ﬁnding DNA hypermethylated genes
and prioritizing these to be sequenced for mutations as well
as prioritizing newly discovered mutated genes to be studied
for promoter methylation.
Figure 8. Comparison of Hypermethylation Frequencies in Human Tumor Samples
Methylation analysis of verified hypermethylome genes in human tissue samples. Twenty genes from the verified gene lists were randomly selected from
the HCT116 top tier (BOLL, DDX43, DKK3, FOXL2, HOXD1, JPH3, NEF3, NEURL, PPP1R14A, RAB32, STK31, and TLR2), HCT116 next tier (SALL4 and TP53AP1),
or SW480 top tier (ZFP42) and analyzed for methylation in CRC cell lines (white columns), normal colon (red columns), or primary tumors (green columns).
Percentage of methylation is indicated on the y-axis, and the abbreviated gene name on the x-axis. We tested at least six different cell lines, 16 to 40
colonic samples from noncancer patients, and between 18 and 61 primary CRC samples for each gene.
doi:10.1371/journal.pgen.0030157.g008
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Gene Hypermethylation and MutationsMaterials and Methods
Cell culture and treatment. HCT116 cells and isogenic genetic
knockout derivatives were maintained as previously described [14].
For drug treatments, log-phase CRC cells were cultured in McCoy’s
5A media (Invitrogen, http://www.invitrogen.com/) containing 10%
BCS and 13 penicillin/streptomycin with 5 lM DAC (stock solution:
1 mM in PBS; Sigma, http://www.sigmaaldrich.com/) for 96 h, replacing
media and DAC every 24 h. Cell treatment with 300 nM TSA (stock
solution: 1.5mM dissolved in ethanol, Sigma) was performed for 18 h.
Control cells underwent mock treatment in parallel with addition of
equal volume of PBS or ethanol without drugs.
Figure 9. Epigenetic Inactivation of NEURL and FOXL2 Genes in Colorectal Cancer Cell Lines and Tumors
(A–D) Methylation and expression analyses. Cell line abbreviations are indicated at the top (A, C), with the upper panel indicating methylation tested by
MSP and expression tested by RT-PCR before ( ) and after (þ) DAC treatment. U indicates unmethylated and M indicates methylated alleles DKO and
water (H2O) controls are indicated on the right panel. Graphical display of the NEURL (B) or FOXL2 (D) promoter CpG islands, with bisulfite sequencing
primers indicated in black, MSP primers indicated in red, and CpG nucleotides as open circles. Transcription start sites are indicated with a green square,
and the 59 and 39 ends are indicated by numbers with respect to the transcription start site. Bisulfite sequencing results (lower panels) in cell lines
(HCT116, RKO, or DKO) or human tissues (normal colon or rectum); unmethylated CpGs are indicated by open circles, methylated CpGs by shaded
circles.
(E) Methylation analysis of the NEURL CpG island in human tumors. Upper panel shows results of primary CRC samples analyzed by MSP. Positive
samples analyzed further by bisulfite sequencing are denoted with an arrow. Lower panel shows bisulfite sequencing results for 15 cloned alleles of
each tumor sample, with the location relative to the transcription start site indicated in bp. Open circles indicate unmethylated CpG dinucleotides and
closed circles indicate methylated dinucleotides.
(F) Methylation analysis of the FOXL2 CpG island in human tumors. Upper panel shows results of primary CRC samples analyzed by MSP. Positive
samples analyzed by bisulfite sequencing are denoted with an arrow. Lower panel shows bisulfite sequencing results for 15 cloned alleles of each tumor
sample, with the location relative to the transcription start site indicated in bp. Open circles indicate unmethylated CpG dinucleotides and closed circles
indicate methylated dinucleotides.
(G) Results of MSP methylation status of FOXL2 and NEURL in colon cancers classified as being microsatellite stable (MSS) or having microsatellite
instability (MSI) by classic criteria.
doi:10.1371/journal.pgen.0030157.g009
Figure 10. Tumor-Suppressor Activity of FOXL2 and NEURL Gene Products In Vitro
(A) ExpressionvectorsencodingfulllengthNEURLorFOXL2,oremptyvector,weretransfectedintoHCT116cells,selectedforhygromycinresistance,andstained.
(B) Resulting colonies were visualized by light microscopy.
(C–E) Colony number resulting from transfection with the indicated plasmid in HCT116 cells (C), RKO (D), or DLD1 cells (E).
(F) GrowthsuppressionofHCT116cellsbyp53.Colonyformation(leftpanel),colonyvisualization(middlepanel),andquantitation(rightpanel)areindicated.
doi:10.1371/journal.pgen.0030157.g010
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Gene Hypermethylation and MutationsMicroarray analysis. Total RNA was harvested from logphase cells
using TRIzol (Invitrogen) and the RNeasy kit (Qiagen, http://www1.
qiagen.com/) according to the manufacturer’s instructions, including
a DNase digestion step. RNA was quantiﬁed using the NanoDrop ND-
100 (http://www.nanodrop.com/) followed by quality assessment with
2100 Bioanalyzer (Agilent Technologies, http://www.agilent.com/).
RNA concentrations for individual samples were greater than
200ng/ll, with 28S/18S ratios greater than 2.2 and RNA integrity of
10 (10 scored as the highest). Sample ampliﬁcation and labeling
procedures were carried out using the Low RNA Input Fluorescent
Linear Ampliﬁcation Kit (Agilent Technologies) according to the
manufacturer’s instructions. The labeled cRNA was puriﬁed using the
RNeasy mini kit (Qiagen) and quantiﬁed. RNA spike-in controls
(Agilent Technologies) were added to RNA samples before ampliﬁ-
cation. Samples (0.75 lg) labeled with Cy3 or Cy5 were mixed with
control targets (Agilent Technologies), assembled on Oligo Micro-
array, hybridized, and processed according to the Agilent microarray
protocol. Scanning was performed with the Agilent G2565BA micro-
array scanner using settings recommended by Agilent Technologies.
Data analysis. All arrays were subject to quality checks recom-
mended by the manufacturer. Images were visually inspected for
artifacts, and distributions of signal and background intensity of both
red and green channels were examined to identify anomalous arrays.
No irregularities were observed, and all arrays were retained and
used. All calculations were performed using the R statistical
computing platform [43] and packages from Bioconductor bioinfor-
matics software project [44–46]. The log ratio of red signal to green
signal was calculated after background subtraction and LoEss
normalization as implemented in the limma package from Biocon-
ductor [46]. Individual arrays were scaled to have the same inter-
quartile range (75th percentile–25th percentile). Log-fold changes
were averaged over dye-swap replicate microarrays to produce a
single set of expression values for each condition. We have deposited
primary array data in the GEO database at the National Center for
Biotechnology Information (NCBI).
Methylation and gene expression analysis. RNA was isolated with
TRIzol Reagent (Invitrogen) according to the manufacturer’s instruc-
tions. For RT-PCR, 1 lg of total RNA was reverse transcribed using
Ready-To-Go You-Prime First-Strand Beads (Amersham Biosciences,
http://www.amersham.com/) with addition of random hexamers (0.2 lg
per reaction). For RT-primer design we used Primer3 (http://frodo.wi.
mit.edu/cgi-bin/primer3/primer3_www.cgi). For MSP analysis, DNA
was extracted following a standard phenol-chloroform extraction
method. Bisulﬁte modiﬁcation of genomic DNA was carried out using
the EZ DNA methylation Kit (Zymo Research, http://www.
zymoresearch.com/). Primer sequences speciﬁc to the unmethylated
and methylated promotor sequences were designed using MSPPrimer
(http://www.mspprimer.org). MSP was performed as previously
described [22]. All PCR products (15 ll of 50-ll total volume for
RT-PCR and 7.5 ll of 25-ll total volume for MSP) were loaded directly
onto 2% agarose gels containing GelStar Nucleic Acid Gel Stain
(Cambrex, http://www.cambrex.com/) and visualized under ultraviolet
illumination. Primer sequences and conditions for MSP, bisulﬁte
sequencing, and RT-PCR are available upon request from the authors.
Figure 11. Comparing Methylation and Mutation Frequency of Cancer Genes in CRC Tumor Samples
(A) Expression of matched CAN genes in normal human colon measured by RT-PCR. Partially expressed and no expression indicated weak or absent
RT-PCR amplification. (B, C) Methylation analysis of CAN genes. Fifty-six CAN genes were located in the top or next tier of one microarray in one or more
cell lines. Of these, 45 genes contained CpG islands. Selected genes from this list with methylation in cell lines (26 genes) were analyzed for methylation
in normal colon (B) and primary CRC (C). Frequency of methylation of these genes is shown as a percentage.
(D) Relationship between methylation status, analyzed by MSP, and mutation for 13 genes overlapping the CAN and hypermethylome gene lists.
doi:10.1371/journal.pgen.0030157.g011
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Gene Hypermethylation and MutationsHuman tumor analysis. Formalin-ﬁxed, parafﬁn-embedded tissues
from primary CRCs were obtained from the archive of the
Department of Pathology of the University Hospital Maastricht,
Maastricht, The Netherlands and Johns Hopkins University Hospital.
Approval was obtained by the Medical Ethical Committees of the
University of Maastricht and the University Hospital Maastricht and
Johns Hopkins University Hospital. DNA was isolated using the
Puregene DNA isolation kit (Gentra Systems, http://www1.qiagen.
com/). FOXL2 and NEURL methylation was analyzed by nested MSP.
MSI analysis was performed by analysis of the BAT-26 mononucleo-
tide repeat.
The primer sequences and PCR conditions for the BAT-26
mononucleotide repeat were used as described previously [47].
Colony Formation Assay. One million HCT116, RKO, or DLD1
cells were plated in six-well dishes (Falcon) and transfected with 5 lg
of plasmid (pIRES-Neo3, Invitrogen) using Lipofectamine 2000
according to the manufacturer’s instructions. Following a 24-h
recovery period, selection in 4 lg/ml gentamycin- (Invitrogen)
containing complete medium was performed for 10 d. Staining,
visualization, and counting of triplicate wells were performed as
previously described [48].
Supporting Information
Figure S1. Sensitivity of Detecting Hypermethylated Genes Compared
with Control Genes
Found at doi:10.1371/journal.pgen.0030157.sg001 (150 KB PPT).
Table S1. Quantitative Estimate of Hypermethylome Size
Found at doi:10.1371/journal.pgen.0030157.st001 (50 KB PPT).
Accession Numbers
We have deposited primary array data in the GEO database at the
NCBI (http://www.ncbi.nlm.nih.gov/geo/). The accession numbers for
the array experiments described in the paper are: GSM107602,
DAC_vs_mock; GSM107603, TSA_VS_mock; GSM107604,
DNMT1_vs_WT; GSM107605, DNMT3B_vs_WT; GSM107606,
DKO_vs_WT; GSM107607, WT_vs_DKO; GSM107660,
DAC_vs_mock_2; GSM107662, TSA_vs_mock_2; GSM107663,
WT_vs_DNMT1; and GSM107664, WT_vs_DNMT3B.
The GEO series in which all ten arrays are linked may be found
under accession number GSE4763.
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